Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TPX-4589 |
Synonyms | |
Therapy Description |
TPX-4589 (LM-302) is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2) targeted antibody linked to monomethyl auristatin E (MMAE), which potentially inhibits proliferation of CLDN18.2-expressing tumor cells and tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S41-S42). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TPX-4589 | LM 302|LM302|LM-302|TPX 4589|TPX4589 | CLDN18.2 Antibody 19 | TPX-4589 (LM-302) is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2) targeted antibody linked to monomethyl auristatin E (MMAE), which potentially inhibits proliferation of CLDN18.2-expressing tumor cells and tumor growth (Eur J Cancer 2022 Vol 174, Supp 1:S41-S42). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05188664 | Phase Ib/II | Toripalimab-tpzi + TPX-4589 TPX-4589 | Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Terminated | AUS | 0 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |